<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617105</url>
  </required_header>
  <id_info>
    <org_study_id>7550</org_study_id>
    <nct_id>NCT05617105</nct_id>
  </id_info>
  <brief_title>Molecular Characterization of Perivascular Epithelioid Cell Tumors</brief_title>
  <acronym>PEComesCells</acronym>
  <official_title>Molecular Characterization of Perivascular Epithelioid Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perivascular epithelioid cell tumors (PEComas) are rare and are characterized by the&#xD;
      expression of myomelanocytic markers. They are a complex family that includes&#xD;
      angiomyolipomas, lymphangioleiomyomatoses and other soft tissue and visceral tumors. Due to&#xD;
      the low prevalence of these tumors, the natural history is unclear; furthermore, a molecular&#xD;
      classification integrating clinical, pathological and molecular parameters has not been&#xD;
      described to date.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To retrospectively describe the percentage of tumors with FISH (Fluorescence In Situ Hybridization) identification of the TFE3 rearrangement out of 100 cases of PEComas diagnosed in France between 01 January 1990 and 15 September 2019</measure>
    <time_frame>Files analysed retrospectively from January 01, 1990 to September 15, 2019 will be examined</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Perivascular Epithelioid Cell Tumor, Malignant</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients having PEComas diagnosed in France between 01/01/1990 and 15/09/2019 and reviewed&#xD;
        by a sarcoma referral pathologist&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major patient (≥18 years)&#xD;
&#xD;
          -  Minor patient (1 to 17 years old)&#xD;
&#xD;
          -  PEComas diagnosed in France between 01/01/1990 and 15/09/2019 and reviewed by a&#xD;
             sarcoma referral pathologist&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Opposition of the patient (or the holders of parental authority) to participate in the&#xD;
             study&#xD;
&#xD;
          -  Biological tissue from a patient who does not meet all the inclusion criteria&#xD;
&#xD;
          -  Classic triphasic angiomyolipoma or lymphangioleiomyomatosis&#xD;
&#xD;
          -  Inability to provide informed information to the subject&#xD;
&#xD;
          -  Patient under court protection&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel MALOUF, MD, PhD</last_name>
    <phone>33 3 88 11 51 41</phone>
    <email>malouf.gabriel@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Oncologie - CHU de Strasbourg - France</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <phone>33 3 88 11 51 41</phone>
      <email>malouf.gabriel@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agathe Bourgmayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline Charon-Barra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Chevreau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Bertucci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loic Chaigneau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelly Firmin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SEVERAC, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youenn DAVIDSON, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perivascular epithelioid cell tumors</keyword>
  <keyword>PEComas</keyword>
  <keyword>Myomelanocytic markers</keyword>
  <keyword>Angiomyolipomas</keyword>
  <keyword>Lymphangioleiomyomatoses</keyword>
  <keyword>Visceral tumors</keyword>
  <keyword>Fluorescence In Situ Hybridization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perivascular Epithelioid Cell Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

